Novel inhibitors of the alphavbeta3 integrin--lead identification strategy.
A novel approach to inhibition of the alphavbeta3 integrin is described, which uses compounds designed to generate nM potency without using the arginine binding site.
Elliot
David
D
AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
Henshaw
Eleanor
E
MacFaul
Philip A
PA
Morley
Andrew D
AD
Newham
Peter
P
Oldham
Keith
K
Page
Ken
K
Rankine
Neil
N
Sharpe
Paul
P
Ting
Attilla
A
Wood
Christine M
CM
D000818:Animals; D001665:Binding Sites; D003198:Computer Simulation; D015195:Drug Design; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009842:Oligopeptides / Q000737:chemistry; D051381:Rats; D054852:Small Molecule Libraries; D013329:Structure-Activity Relationship
D039302:Integrin alphaVbeta3; D009842:Oligopeptides; D054852:Small Molecule Libraries; C047981:arginyl-glycyl-aspartic acid